page|135
|||资产负债表||
编制单位：丽珠医药集团股份有限公司|||||金额单位：人民币元
||年末数||年初数|
项      目|附注||||
||合并|公司|合并|公司
流动资产：|||||
货币资金|五、1|8,855,408,402.78|7,772,918,903.18|8,587,927,272.41|7,505,401,614.22
交易性金融资产|五、2|17,191,861.74|8,035,940.56|15,934,738.20|7,267,953.42
应收票据|五、3|952,945,194.97|569,150,368.41|1,029,370,542.77|606,560,125.42
应收账款|五、4|1,472,438,936.26|652,604,102.82|1,381,706,955.95|601,743,929.08
应收款项融资|||||
预付款项|五、5|186,231,922.16|23,285,852.64|169,765,301.71|26,503,604.37
其他应收款|五、6|91,848,022.04|1,620,041,222.11|49,482,179.59|1,779,658,972.33
其中：应收利息|||||
应收股利||11,475,000.00|573,412,484.96||599,078,865.48
存货|五、7|1,168,854,337.03|553,618,797.04|1,117,007,240.91|483,740,282.91
合同资产|||||
持有待售资产|||||
一年内到期的非流动资产 五、8||17,497,288.62|17,497,288.62|10,869,100.00|10,869,100.00
其他流动资产|五、9|110,786,443.02|4,752,848.61|109,664,922.90|3,720.38
流动资产合计||12,873,202,408.62|11,221,905,323.99|12,471,728,254.44|11,021,749,302.13
非流动资产：|||||
债权投资|||||
其他债权投资|||||
长期应收款|五、10|10,828,143.63|10,828,143.63|20,299,509.76|20,299,509.76
长期股权投资|五、11|171,498,988.56|1,901,157,584.00|188,106,109.58|1,906,138,109.75
其他权益工具投资|五、12|479,737,808.86|118,629,608.84|407,707,119.32|80,503,108.84
其他非流动金融资产|||||
投资性房地产|||||
固定资产|五、13|3,160,096,367.19|83,020,764.96|3,217,576,074.00|77,680,302.35
在建工程|五、14|233,489,857.85|114,259.61|184,518,928.04|1,729,987.35
生产性生物资产|||||
油气资产|||||
使用权资产|||||
无形资产|五、15|229,559,613.00|30,340,512.63|244,193,325.80|25,547,418.64
开发支出|五、16|148,504,020.49||81,146,586.57|4,740,370.24
商誉|五、17|103,040,497.85||103,040,497.85|
长期待摊费用|五、18|111,340,713.49|5,645,604.20|113,346,522.83|1,643,638.99
递延所得税资产|五、19|182,659,491.39|32,547,576.65|141,596,264.49|30,325,432.85
其他非流动资产|五、20|272,505,206.28|95,598,763.52|264,087,667.70|90,929,898.90
非流动资产合计||5,103,260,708.59|2,277,882,818.04|4,965,618,605.94|2,239,537,777.67
资产总计||17,976,463,117.21|13,499,788,142.03|17,437,346,860.38|13,261,287,079.80
page|136
|||资产负债表（续）|||
编制单位：丽珠医药集团股份有限公司||||||金额单位：人民币元
|||年末数||年初数|
项|目|附注||||
|||合并|公司|合并|公司
流动负债：||||||
短期借款||五、21|1,360,840,657.32|1,151,369,666.66|1,500,000,000.00|1,500,000,000.00
交易性金融负债||五、22|13,916.00||85,294.16|
应付票据||五、23|715,986,816.20|7,139,310.75|718,590,036.85|22,892,011.81
应付账款||五、24|547,102,924.99|584,136,134.88|636,324,506.52|370,669,222.77
预收款项||||||
合同负债||五、25|151,765,150.53|41,484,759.54|115,973,464.09|40,208,856.21
应付职工薪酬||五、26|278,117,911.92|74,999,108.16|186,046,426.55|33,347,783.68
应交税费||五、27|223,339,525.21|13,776,226.89|245,057,455.45|52,232,361.86
其他应付款||五、28|2,016,490,501.54|4,689,008,436.20|1,967,100,817.25|3,851,428,656.70
其中：应付利息||||||
应付股利|||90,179,524.72|20,174.46|97,536,288.17|20,174.46
持有待售负债||||||
一年内到期的非流动负债||五、29|||400,000.00|
其他流动负债||||||
|流动负债合计||5,293,657,403.71|6,561,913,643.08|5,369,578,000.87|5,870,778,893.03
非流动负债：||||||
长期借款||五、30|||700,000.00|
应付债券||||||
租赁负债||||||
长期应付款||||||
长期应付职工薪酬||||||
预计负债||||||
递延收益||五、31|246,683,181.60|72,502,157.94|262,712,220.34|77,673,338.51
递延所得税负债||五、19|90,884,958.20|16,309,446.79|54,479,730.16|7,868,473.39
其他非流动负债||五、32|70,000,000.00|||
|非流动负债合计||407,568,139.80|88,811,604.73|317,891,950.50|85,541,811.90
|负债合计||5,701,225,543.51|6,650,725,247.81|5,687,469,951.37|5,956,320,704.93
股本||五、33|934,762,675.00|934,762,675.00|719,050,240.00|719,050,240.00
其他权益工具||||||
其中：优先股||||||
永续债||||||
资本公积||五、34|1,163,404,748.17|1,527,410,001.24|1,362,250,389.67|1,726,897,983.73
减：库存股||五、35|||25,208.04|25,208.04
其他综合收益||五、36|26,403,971.65|31,474,909.33|-29,164,814.15|
专项储备||||||
盈余公积||五、37|623,178,143.29|418,215,089.71|587,255,162.90|382,292,109.32
未分配利润||五、38|8,419,002,908.40|3,937,200,218.94|8,012,611,700.26|4,476,751,249.86
归属于母公司股东权益合计|||11,166,752,446.51|6,849,062,894.22|10,651,977,470.64|7,304,966,374.87
少数股东权益|||1,108,485,127.19||1,097,899,438.37|
|股东（或所有者）权益合计||12,275,237,573.70|6,849,062,894.22|11,749,876,909.01|7,304,966,374.87
|负债和股东（或所有者）权益总计||17,976,463,117.21|13,499,788,142.03|17,437,346,860.38|13,261,287,079.80
page|137
利润表|||
编制单位：丽珠医药集团股份有限公司||金额单位：人民币元|
|本年数|上年数|
项      目     附注|||
合并|公司|合并|公司
一、营业收入 五、39   9,384,695,835.01|4,905,049,183.64|8,860,655,670.73|4,630,876,965.08
减：营业成本 五、39   3,391,728,260.19|3,033,128,400.72|3,359,655,064.11|2,769,742,007.02
税金及附加 五、40   108,757,407.34|24,877,723.18|118,454,266.51|27,421,306.18
销售费用 五、41   3,093,219,804.38|1,518,031,878.59|3,267,279,529.29|1,761,642,901.70
管理费用 五、42   629,346,060.48|210,272,003.18|546,375,495.41|178,946,072.79
研发费用 五、43   732,891,738.02|244,316,283.21|548,972,707.16|166,084,628.20
财务费用 五、44    -220,799,167.69|-197,022,584.14|-251,952,496.18|-213,483,424.99
其中：利息费用    7,255,024.45|50,955,723.77|16,772,638.85|45,192,299.74
利息收入    226,434,815.93|248,785,218.67|236,174,743.57|271,983,961.62
加：其他收益 五、45   156,194,635.50|71,618,167.71|85,097,367.17|20,281,040.34
投资收益(损失以“-”号填列） 五、46   -19,597,761.68|252,210,453.14|-42,445,887.41|750,747,652.69
其中：对联营企业和合营企业的投资收益    -10,686,084.85|-12,699,314.85|-6,186,649.16|-15,239,316.17
以摊余成本计量的金融资产终止确|||
认收益（损失以“-”号填列）|||
净敞口套期收益(损失以“-”号填列）|||
公允价值变动收益(损失以“-”号填列） 五、47   1,328,501.70|767,987.14|-2,410,266.97|-2,598,444.42
信用减值损失(损失以“-”号填列） 五、48   -4,860,224.48|-246,721.68|30,700,999.19|21,164,034.42
资产减值损失(损失以“-”号填列） 五、49   -53,224,067.26|-15,051,663.80|-67,768,499.83|-5,076,644.58
资产处置收益(损失以“-”号填列） 五、50   460,273.31|190,797.13|-549,283.16|-110,725.33
二、营业利润(亏损以“-”号填列）    1,729,853,089.38|380,934,498.54|1,274,495,533.42|724,930,387.30
加：营业外收入 五、51   11,483,490.34|220,086.88|176,898,473.07|150,676,949.07
减：营业外支出 五、52   13,794,185.53|4,566,827.20|34,719,651.84|4,518,887.74
三、利润总额(亏损总额以“-”号填列）    1,727,542,394.19|376,587,758.22|1,416,674,354.65|871,088,448.63
减：所得税费用 五、53   265,964,834.90|17,357,954.35|234,959,635.62|12,510,282.31
四、净利润(净亏损以“-”号填列）    1,461,577,559.29|359,229,803.87|1,181,714,719.03|858,578,166.32
（一）按经营持续性分类：|||
其中：持续经营净利润（净亏损以“-”号填列）    1,461,577,559.29|359,229,803.87|1,181,714,719.03|858,578,166.32
终止经营净利润（净亏损以“-”号填列）|||
（二）按所有权归属分类：|||
其中： 归属于母公司股东的净利润（净亏损以“-”|||
1,302,875,440.93|359,229,803.87|1,082,174,905.98|858,578,166.32
号填列）|||
少数股东损益（净亏损以“-”号填列）    158,702,118.36||99,539,813.05|
五、其他综合收益的税后净额    58,697,018.11|31,474,909.33|26,035,358.56|-
归属于母公司股东的其他综合收益的税后净额    55,568,785.80|31,474,909.33|23,734,115.37|-
（一）不能重分类进损益的其他综合收益    39,155,030.34|31,319,525.00|9,849,816.91|-
1、重新计量设定受益计划变动额|||
2、权益法下不能转损益的其他综合收益|||
3、其他权益工具投资公允价值变动    39,155,030.34|31,319,525.00|9,849,816.91|
4、企业自身信用风险公允价值变动|||
5、其他|||
（二）将重分类进损益的其他综合收益    16,413,755.46|155,384.33|13,884,298.46|-
1、权益法下可转损益的其他综合收益    155,384.33|155,384.33||
3、其他债权投资公允价值变动|||
3、金融资产重分类计入其他综合收益的金额|||
4、其他债权投资信用减值准备|||
5、现金流量套期储备（现金流量套期损益的|||
有效部分）|||
6、外币财务报表折算差额    16,258,371.13||13,884,298.46|
7、其他|||
归属于少数股东的其他综合收益的税后净额    3,128,232.31||2,301,243.19|
六、综合收益总额    1,520,274,577.40|390,704,713.20|1,207,750,077.59|858,578,166.32
归属于母公司股东的综合收益总额    1,358,444,226.73|390,704,713.20|1,105,909,021.35|858,578,166.32
归属于少数股东的综合收益总额    161,830,350.67||101,841,056.24|
七、每股收益|||
（一）基本每股收益    1.39||1.16|
（二）稀释每股收益    1.39||1.16|
